Incretin-mimetic therapies and pancreatic disease: a review of observational data

References

• Egan AG, Blind E, Dunder K, et al. Pancreatic safety of incretin-based drugs – FDA and EMA assessment. N Engl J Med 2014;370:794-7
   PubMed Web of Science ®Google Scholar
• Meisterfeld R, Ehehalt F, Saegar HD, et al. Pancreatic disorders and diabetes mellitus. Exp Clinl Endocrinol Diabetes 2008;116(Suppl 1):S7-12
   PubMed Web of Science ®Google Scholar
• Eland IA, Sundstrom A, Velo GP, et al. Antihypertensive medication and the risk of acute pancreatitis: the European case–control study on drug-induced acute pancreatitis (EDIP). Scand J Gastroenterol 2006;41:1484-90
   PubMed Web of Science ®Google Scholar
• Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010;33:2349-54
   PubMed Web of Science ®Google Scholar
• Girman CJ, Kou TD, Cai B, et al. Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obes Metabol 2010;12:766-71
   PubMed Web of Science ®Google Scholar
• Gonzalez-Perez A, Schlienger RG, Garcia Rodriguez LA. Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study. Diabetes Care 2010;33:2580-5
   PubMed Web of Science ®Google Scholar
• Lai SW, Muo CH, Liao KF, et al. Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: a population-based cohort study in Taiwan. Am J Gastroenterol 2011;106:1697-704
   PubMed Web of Science ®Google Scholar
• Noel RA, Braun DK, Patterson RE, et al. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective cohort study. Diabetes Care 2009;32:834-8
   PubMed Web of Science ®Google Scholar
• Shen HN, Chang YH, Chen HF, et al. Increased risk of severe acute pancreatitis in patients with diabetes. Diabet Med 2012;29:1419-24
   PubMed Web of Science ®Google Scholar
• Urushihara H, Taketsuna M, Liu Y, et al. Increased risk of acute pancreatitis in patients with type 2 diabetes: an observational study using a Japanese hospital database. PloS One 2012;7:e53224
   PubMed Web of Science ®Google Scholar
• Xue Y, Sheng Y, Dai H, et al. Risk of development of acute pancreatitis with pre-existing diabetes: a meta-analysis. Eur J Gastroenterol Hepatol 2012;24:1092-8
   PubMed Web of Science ®Google Scholar
• Li D, Yeung SC, Hassan MM, et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009;137:482-8
   PubMed Web of Science ®Google Scholar
• Ansary-Moghaddam A, Huxley R, Barzi F, et al. The effect of modifiable risk factors on pancreatic cancer mortality in populations of the Asia-Pacific region. Canc Epidemiol Biomarkers Prev 2006;15:2435-40
   PubMed Web of Science ®Google Scholar
• Arnold LD, Patel AV, Yan Y, et al. Are racial disparities in pancreatic cancer explained by smoking and overweight/obesity? Canc Epidemiol Biomarkers Prev 2009;18:2397-405
   PubMed Web of Science ®Google Scholar
• Bonelli L, Aste H, Bovo P, et al. Exocrine pancreatic cancer, cigarette smoking, and diabetes mellitus: a case–control study in northern Italy. Pancreas 2003;27:143-9
   PubMed Web of Science ®Google Scholar
• Bosetti C, Rosato V, Polesel J, et al. Diabetes mellitus and cancer risk in a network of case–control studies. Nutr Canc 2012;64:643-51
   PubMed Web of Science ®Google Scholar
• Brodovicz KG, Kou TD, Alexander CM, et al. Impact of diabetes duration and chronic pancreatitis on the association between type 2 diabetes and pancreatic cancer risk. Diabetes Obes Metabol 2012;14:1123-8
   PubMed Web of Science ®Google Scholar
• Chodick G, Heymann AD, Rosenmann L, et al. Diabetes and risk of incident cancer: a large population-based cohort study in Israel. Canc Causes Contr 2010;21:879-87
   PubMed Web of Science ®Google Scholar
• Hassan MM, Bondy ML, Wolff RA, et al. Risk factors for pancreatic cancer: case–control study. Am J Gastroenterol 2007;102:2696-707
   PubMed Web of Science ®Google Scholar
• Hemminki K, Li X, Sundquist J, Sundquist K. Risk of cancer following hospitalization for type 2 diabetes. Oncologist 2010;15:548-55
   PubMed Web of Science ®Google Scholar
• Inoue M, Iwasaki M, Otani T, et al. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. Arch Intern Med 2006;166:1871-7
   PubMed Web of Science ®Google Scholar
• Jamal MM, Yoon EJ, Vega KJ, et al. Diabetes mellitus as a risk factor for gastrointestinal cancer among American veterans. World J Gastroenterol 2009;15:5274-8
   PubMed Web of Science ®Google Scholar
• Johnson JA, Bowker SL, Richardson K, et al. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential detection bias. Diabetologia 2011;54:2263-71
   PubMed Web of Science ®Google Scholar
• Luo J, Iwasaki M, Inoue M, et al. Body mass index, physical activity and the risk of pancreatic cancer in relation to smoking status and history of diabetes: a large-scale population-based cohort study in Japan – the JPHC study. Canc Causes Contr 2007;18:603-12
   PubMed Web of Science ®Google Scholar
• Stevens RJ, Roddam AW, Spencer EA, et al. Factors associated with incident and fatal pancreatic cancer in a cohort of middle-aged women. Int J Canc 2009;124:2400-5
   PubMed Web of Science ®Google Scholar
• Wang F, Gupta S, Holly EA. Diabetes mellitus and pancreatic cancer in a population-based case–control study in the San Francisco Bay Area, California. Canc Epidemiol Biomarkers Prev 2006;15:1458-63
   PubMed Web of Science ®Google Scholar
• Batty GD, Shipley MJ, Marmot M, et al. Diabetes status and post-load plasma glucose concentration in relation to site-specific cancer mortality: findings from the original Whitehall study. Canc Causes Contr 2004;15:873-81
   PubMed Web of Science ®Google Scholar
• Bodmer M, Becker C, Meier C, et al. Use of antidiabetic agents and the risk of pancreatic cancer: a case–control analysis. Am J Gastroenterol 2012;107:620-6
   PubMed Web of Science ®Google Scholar
• Khan M, Mori M, Fujino Y, et al. Site-specific cancer risk due to diabetes mellitus history: evidence from the Japan Collaborative Cohort (JACC) Study. Asian Pacific J Canc Prev 2006;7:253-9
   PubMedGoogle Scholar
• Rousseau MC, Parent ME, Pollak MN, et al. Diabetes mellitus and cancer risk in a population-based case–control study among men from Montreal, Canada. Int J Canc 2006;118:2105-9
   PubMed Web of Science ®Google Scholar
• Ben Q, Xu M, Ning X, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Canc 2011;47:1928-37
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. CA: a Cancer Journal for Clinicians 2010;60:207-21
   PubMed Web of Science ®Google Scholar
• Wells G, Shea B, O’Connell J, et al. The Newcastle–Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxfordasp [Last accessed 1 August 2013]
   Google Scholar
• Raschi E, Piccinni C, Poluzzi E, et al. The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database. Acta Diabetologica 2011;50:569-77
   PubMed Web of Science ®Google Scholar
• Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 2011;141:150-6
   PubMed Web of Science ®Google Scholar
• Butler PC, Elashoff M, Elashoff R, et al. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care 2013;36:2118-25
   PubMed Web of Science ®Google Scholar
• Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin 2009;25:1019-27
   PubMed Web of Science ®Google Scholar
• Dore DD, Bloomgren GL, Wenten M, et al. A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metabol 2011;13:559-66
   PubMed Web of Science ®Google Scholar
• Dore DD, Hussein M, Hoffman C, et al. A pooled analysis of exenatide use and risk of acute pancreatitis. Curr Med Res Opin 2013;29:1577-86
   Google Scholar
• Funch D, Gydesen H, Tornoe K, et al. A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. Diabetes Obes Metabol 2013;16:273-5
   Google Scholar
• Li X, Zhang Z, Duke J. Glucagon-like peptide 1-based therapies and risk of pancreatitis: a self-controlled case series analysis. Pharmacoepidemiol Drug Saf 2013;23:234-9
   Web of Science ®Google Scholar
• Romley JA, Goldman DP, Solomon M, et al. Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population. Diabetes Technol Therapeut 2012;14:904-11
   PubMed Web of Science ®Google Scholar
• Singh S, Chang HY, Richards TM, et al. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case–control study. JAMA Internal Medicine 2013;173:534-9
   PubMed Web of Science ®Google Scholar
• Wenten M, Gaebler JA, Hussein M, et al. Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study. Diabet Med 2012;29:1412-18
   PubMed Web of Science ®Google Scholar
• Andersen DK, Andren-Sandberg A, Duell EJ, et al. Pancreatitis–diabetes–pancreatic cancer: summary of an NIDDK-NCI workshop. Pancreas 2013;42:1227-37
   PubMed Web of Science ®Google Scholar
• Alves C, Batel-Marques F, Macedo AF. A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer. Diabetes Res Clin Pract 2012;98:271-84
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Information for Healthcare Professionals: Exenatide (marketed as Byetta). Update August 2008. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm [Last accessed 7 May 2014]
   Google Scholar
• Moores K, Gilchrist B, Carnahan R, et al. A systematic review of validated methods for identifying pancreatitis using administrative data. Pharmacoepidemiol Drug Saf 2012;21(Suppl 1):194-202
   PubMedGoogle Scholar
• Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metabol 2013;16:48-56
   Google Scholar
• Macconell L, Brown C, Gurney K, et al. Safety and tolerability of exenatide twice daily in patients with type 2 diabetes: integrated analysis of 5594 patients from 19 placebo-controlled and comparator-controlled clinical trials. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012;5:29-41
   PubMedGoogle Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26
   PubMed Web of Science ®Google Scholar
• Friedlin J, Overhage M, Al-Haddad MA, et al. Comparing methods for identifying pancreatic cancer patients using electronic data sources. AMIA Annual Symposium Proceedings 2010;2010:237-41
   PubMedGoogle Scholar
• Furu K, Wettermark B, Andersen M, et al. The Nordic countries as a cohort for pharmacoepidemiological research. Basic Clin Pharmacol Toxicol 2010;106:86-94
   PubMed Web of Science ®Google Scholar